{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:52:39Z","timestamp":1792515159848,"version":"4.5.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T00:00:00Z","timestamp":1498694400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00109-017-1562-0","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T22:06:53Z","timestamp":1498687613000},"page":"1043-1052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration"],"prefix":"10.1007","volume":"95","author":[{"given":"Adeline A.","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M.","family":"Hemsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,29]]},"reference":[{"key":"1562_CR1","doi-asserted-by":"crossref","first-page":"20423","DOI":"10.1074\/jbc.R110.134452","volume":"285","author":"EB Vitner","year":"2010","unstructured":"Vitner EB, Platt FM, Futerman AH (2010) Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 285:20423\u201320427","journal-title":"J Biol Chem"},{"key":"1562_CR2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","volume":"12","author":"R Pinto","year":"2004","unstructured":"Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, Pinto E, Silva E, Rocha S, Marcao A et al (2004) Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 12:87\u201392","journal-title":"Eur J Hum Genet"},{"key":"1562_CR3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249\u2013254","journal-title":"JAMA"},{"key":"1562_CR4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","volume":"105","author":"BJ Poorthuis","year":"1999","unstructured":"Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151\u2013156","journal-title":"Hum Genet"},{"key":"1562_CR5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","volume":"30","author":"WL Hwu","year":"2009","unstructured":"Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, Yeh HY, Chao MC, Lin SJ, Kitagawa T et al (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 30:1397\u20131405","journal-title":"Hum Mutat"},{"key":"1562_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79:31\u201340","journal-title":"Am J Hum Genet"},{"key":"1562_CR7","doi-asserted-by":"crossref","DOI":"10.1542\/peds.105.1.e10","volume":"105","author":"DA Applegarth","year":"2000","unstructured":"Applegarth DA, Toone JR, Lowry RB (2000) Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 105:e10","journal-title":"Pediatrics"},{"key":"1562_CR8","doi-asserted-by":"crossref","first-page":"9695","DOI":"10.1073\/pnas.88.21.9695","volume":"88","author":"HS Scott","year":"1991","unstructured":"Scott HS, Anson DS, Orsborn AM, Nelson PV, Clements PR, Morris CP, Hopwood JJ (1991) Human alpha-L-iduronidase: cDNA isolation and expression. Proc Natl Acad Sci U S A 88:9695\u20139699","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1562_CR9","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1073\/pnas.87.21.8531","volume":"87","author":"PJ Wilson","year":"1990","unstructured":"Wilson PJ, Morris CP, Anson DS, Occhiodoro T, Bielicki J, Clements PR, Hopwood JJ (1990) Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc Natl Acad Sci U S A 87:8531\u20138535","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1562_CR10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng1295-465","volume":"11","author":"HS Scott","year":"1995","unstructured":"Scott HS, Blanch L, Guo X-H, Freeman VC, Orsborn A, Baker E, Sutherland GR, Morris P, Hopwood JJ (1995) Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nat Genet 11:465\u2013467","journal-title":"Nat Genet"},{"key":"1562_CR11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/hmg\/5.6.771","volume":"5","author":"B Weber","year":"1996","unstructured":"Weber B, Blanch L, Clements PR, Scott HS, Hopwood JJ (1996) Cloning and expression of the gene involved in Sanfilippo B syndrome (Mucopolysaccharidosis III B). Hum Mol Genet 5:771\u2013777","journal-title":"Hum Mol Genet"},{"key":"1562_CR12","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1073\/pnas.93.12.6101","volume":"93","author":"HG Zhao","year":"1996","unstructured":"Zhao HG, Li HH, Bach G, Schmidtchen A, Neufeld EF (1996) The molecular basis of Sanfilippo syndrome type B. Proc Natl Acad Sci U S A 93:6101\u20136105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1562_CR13","first-page":"381","volume":"7","author":"JJ Hopwood","year":"1990","unstructured":"Hopwood JJ, Morris CP (1990) The mucopolysaccharidoses. Diagnosis, molecular genetics and treatment. Mol Biol Med 7:381\u2013404","journal-title":"Mol Biol Med"},{"key":"1562_CR14","doi-asserted-by":"crossref","first-page":"12115","DOI":"10.1016\/S0021-9258(18)63825-6","volume":"264","author":"NM Dahms","year":"1989","unstructured":"Dahms NM, Lobel P, Kornfeld S (1989) Mannose 6-phosphate receptors and lysosomal enzyme targeting. J Biol Chem 264:12115\u201312118","journal-title":"J Biol Chem"},{"key":"1562_CR15","unstructured":"Hopwood JJ, Brooks DA (1997) An introduction to the basic science and biology of the lysosome and storage disorders. In: Appelgarth DA (ed) organelle diseases chapman and hall Medical, London, pp. 7-35"},{"key":"1562_CR16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.bi.61.070192.001515","volume":"61","author":"S Kornfeld","year":"1992","unstructured":"Kornfeld S (1992) Structure and function of the mannose 6-phosphate\/insulinlike growth factor II receptors. Annu Rev Biochem 61:307\u2013330","journal-title":"Annu Rev Biochem"},{"key":"1562_CR17","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1083\/jcb.103.4.1235","volume":"103","author":"WJ Brown","year":"1986","unstructured":"Brown WJ, Goodhouse J, Farquhar MG (1986) Mannose-6-phosphate receptors for lysosomal enzymes cycle between the Golgi complex and endosomes. J Cell Biol 103:1235\u20131247","journal-title":"J Cell Biol"},{"key":"1562_CR18","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.1073\/pnas.78.11.6967","volume":"78","author":"MC Willingham","year":"1981","unstructured":"Willingham MC, Pastan IH, Sahagian GG, Jourdian GW, Neufeld EF (1981) Morphologic study of the internalization of a lysosomal enzyme by the mannose 6-phosphate receptor in cultured Chinese hamster ovary cells. Proc Natl Acad Sci U S A 78:6967\u20136971","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1562_CR19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF01923507","volume":"48","author":"A Hasilik","year":"1992","unstructured":"Hasilik A (1992) The early and late processing of lysosomal enzymes: proteolysis and compartmentation. Experientia 48:130\u2013151","journal-title":"Experientia"},{"key":"1562_CR20","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1073\/pnas.88.7.2788","volume":"88","author":"LG Smith","year":"1991","unstructured":"Smith LG, Weissman IL, Heimfeld S (1991) Clonal analysis of hematopoietic stem-cell differentiation in vivo. Proc Natl Acad Sci U S A 88:2788\u20132792","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1562_CR21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(81)91046-1","volume":"2","author":"JR Hobbs","year":"1981","unstructured":"Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K, James DC, Lucas CF, Rogers TR, Benson PF et al (1981) Reversal of clinical features of Hurler\u2019s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 2:709\u2013712","journal-title":"Lancet"},{"key":"1562_CR22","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","volume":"125","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, Wynn RF, Orchard PJ, O'Meara A, Veys P, Fischer A, Valayannopoulos V, Neven B, Rovelli A, Prasad VK et al (2015) Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood 125:2164\u20132172","journal-title":"Blood"},{"key":"1562_CR23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00281-004-0166-2","volume":"26","author":"W Krivit","year":"2004","unstructured":"Krivit W (2004) Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immun 26:119\u2013132","journal-title":"Springer Semin Immun"},{"key":"1562_CR24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bmt.1701141","volume":"21","author":"Y Yamada","year":"1998","unstructured":"Yamada Y, Kato K, Sukegawa K, Tomatsu S, Fukuda S, Emura S, Kojima S, Matsuyama T, Sly WS, Kondo N et al (1998) Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619v mutation. Bone Marrow Transplant 21:629\u2013634","journal-title":"Bone Marrow Transplant"},{"key":"1562_CR25","doi-asserted-by":"publisher","unstructured":"Montano AM, Lock-Hock N, Steiner RD, Graham BH, Szlago M, Greenstein R, Pineda M, Gonzalez-Meneses A, Coker M, Bartholomew D et al (2016) Clinical course of sly syndrome (mucopolysaccharidosis type VII). J Med Genet. doi: 10.1136\/jmedgenet-2015-103322","DOI":"10.1136\/jmedgenet-2015-103322"},{"key":"1562_CR26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jpeds.2008.11.041","volume":"154","author":"N Guffon","year":"2009","unstructured":"Guffon N, Bertrand Y, Forest I, Fouilhoux A, Froissart R (2009) Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr 154:733\u2013737","journal-title":"J Pediatr"},{"key":"1562_CR27","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1023\/A:1005525931994","volume":"22","author":"A Vellodi","year":"1999","unstructured":"Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE (1999) Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 22:638\u2013648","journal-title":"J Inherit Metab Dis"},{"key":"1562_CR28","first-page":"1398","volume":"345","author":"PM Hoogerbrugge","year":"1995","unstructured":"Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ, O'Meara A, Cornu G, Souillet G, Frappaz D et al (1995) Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation Lancet 345:1398\u20131402","journal-title":"The European Group for Bone Marrow Transplantation Lancet"},{"key":"1562_CR29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF00710053","volume":"18","author":"EG Shapiro","year":"1995","unstructured":"Shapiro EG, Lockman LA, Balthazor M, Krivit W (1995) Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 18:413\u2013429","journal-title":"J Inherit Metab Dis"},{"key":"1562_CR30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ymgme.2014.10.017","volume":"114","author":"JE Fox","year":"2015","unstructured":"Fox JE, Volpe L, Bullaro J, Kakkis ED, Sly WS (2015) First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient. Mol Genet Metab 114:203\u2013208","journal-title":"Mol Genet Metab"},{"key":"1562_CR31","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/ajmg.a.32294","volume":"146A","author":"MV Munoz-Rojas","year":"2008","unstructured":"Munoz-Rojas MV, Vieira T, Costa R, Fagondes S, John A, Jardim LB, Vedolin LM, Raymundo M, Dickson PI, Kakkis E et al (2008) Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A 146A:2538\u20132544","journal-title":"Am J Med Genet A"},{"key":"1562_CR32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","volume":"18","author":"J Muenzer","year":"2016","unstructured":"Muenzer J, Hendriksz CJ, Fan Z, Vijayaraghavan S, Perry V, Santra S, Solanki GA, Mascelli MA, Pan L, Wang N et al (2016) A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med 18:73\u201381","journal-title":"Genet Med"},{"key":"1562_CR33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","volume":"118","author":"SA Jones","year":"2016","unstructured":"Jones SA, Breen C, Heap F, Rust S, de Ruijter J, Tump E, Marchal JP, Pan L, Qiu Y, Chung JK et al (2016) A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab 118:198\u2013205","journal-title":"Mol Genet Metab"},{"key":"1562_CR34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ymgme.2006.01.010","volume":"88","author":"E Beutler","year":"2006","unstructured":"Beutler E (2006) Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab 88:208\u2013215","journal-title":"Mol Genet Metab"},{"key":"1562_CR35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bcmd.2010.05.002","volume":"46","author":"J Goldblatt","year":"2011","unstructured":"Goldblatt J, Fletcher JM, McGill J, Szer J, Wilson M (2011) Enzyme replacement therapy \"drug holiday\": results from an unexpected shortage of an orphan drug supply in Australia. Blood Cells Mol Dis 46:107\u2013110","journal-title":"Blood Cells Mol Dis"},{"key":"1562_CR36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ymgme.2005.11.017","volume":"87","author":"F Chen","year":"2006","unstructured":"Chen F, Vitry S, Hocquemiller M, Desmaris N, Ausseil J, Heard JM (2006) alpha-L-Iduronidase transport in neurites. Mol Genet Metab 87:349\u2013358","journal-title":"Mol Genet Metab"},{"key":"1562_CR37","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1523\/JNEUROSCI.22-15-06437.2002","volume":"22","author":"MA Passini","year":"2002","unstructured":"Passini MA, Lee EB, Heuer GG, Wolfe JH (2002) Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J Neurosci 22:6437\u20136446","journal-title":"J Neurosci"},{"key":"1562_CR38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ymthe.2004.03.018","volume":"10","author":"AK Hennig","year":"2004","unstructured":"Hennig AK, Ogilvie JM, Ohlemiller KK, Timmers AM, Hauswirth WW, Sands MS (2004) AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice. Mol Ther 10:106\u2013116","journal-title":"Mol Ther"},{"key":"1562_CR39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","volume":"13","author":"MS Sands","year":"2006","unstructured":"Sands MS, Davidson BL (2006) Gene therapy for lysosomal storage diseases. Mol Ther 13:839\u2013849","journal-title":"Mol Ther"},{"key":"1562_CR40","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2012.140","volume":"23","author":"BJ Byrne","year":"2012","unstructured":"Byrne BJ, Falk DJ, Clement N, Mah CS (2012) Gene therapy approaches for lysosomal storage disease: next-generation treatment. Hum Gene Ther 23:808\u2013815","journal-title":"Hum Gene Ther"},{"key":"1562_CR41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/jgm.1028","volume":"9","author":"EL Aronovich","year":"2007","unstructured":"Aronovich EL, Bell JB, Belur LR, Gunther R, Koniar B, Erickson DC, Schachern PA, Matise I, McIvor RS, Whitley CB et al (2007) Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses. J Gene Med 9:403\u2013415","journal-title":"J Gene Med"},{"key":"1562_CR42","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1089\/hum.2005.16.551","volume":"16","author":"S Zolotukhin","year":"2005","unstructured":"Zolotukhin S (2005) Production of recombinant adeno-associated virus vectors. Hum Gene Ther 16:551\u2013557","journal-title":"Hum Gene Ther"},{"key":"1562_CR43","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1002\/j.1460-2075.1991.tb04964.x","volume":"10","author":"RJ Samulski","year":"1991","unstructured":"Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA (1991) Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 10:3941\u20133950","journal-title":"EMBO J"},{"key":"1562_CR44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/hum.2006.17.253","volume":"17","author":"C Baum","year":"2006","unstructured":"Baum C, Kustikova O, Modlich U, Li Z, Fehse B (2006) Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 17:253\u2013263","journal-title":"Hum Gene Ther"},{"key":"1562_CR45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/1566523054064995","volume":"5","author":"TJ McCown","year":"2005","unstructured":"McCown TJ (2005) Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 5:333\u2013338","journal-title":"Curr Gene Ther"},{"key":"1562_CR46","doi-asserted-by":"crossref","first-page":"8446","DOI":"10.1128\/JVI.76.16.8446-8454.2002","volume":"76","author":"MY Mastakov","year":"2002","unstructured":"Mastakov MY, Baer K, Symes CW, Leichtlein CB, Kotin RM, During MJ (2002) Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J Virol 76:8446\u20138454","journal-title":"J Virol"},{"key":"1562_CR47","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/sj.gt.3300994","volume":"6","author":"N Chirmule","year":"1999","unstructured":"Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6:1574\u20131583","journal-title":"Gene Ther"},{"key":"1562_CR48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coviro.2016.08.003","volume":"21","author":"A Srivastava","year":"2016","unstructured":"Srivastava A (2016) In vivo tissue-tropism of adeno-associated viral vectors. Curr Opin Virol 21:75\u201380","journal-title":"Curr Opin Virol"},{"key":"1562_CR49","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1073\/pnas.55.6.1467","volume":"55","author":"MD Hoggan","year":"1966","unstructured":"Hoggan MD, Blacklow NR, Rowe WP (1966) Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci U S A 55:1467\u20131474","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1562_CR50","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1073\/pnas.79.6.2077","volume":"79","author":"RJ Samulski","year":"1982","unstructured":"Samulski RJ, Berns KI, Tan M, Muzyczka N (1982) Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A 79:2077\u20132081","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1562_CR51","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/JVI.76.2.791-801.2002","volume":"76","author":"JE Rabinowitz","year":"2002","unstructured":"Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ (2002) Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76:791\u2013801","journal-title":"J Virol"},{"key":"1562_CR52","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","volume":"10","author":"C Burger","year":"2004","unstructured":"Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10:302\u2013317","journal-title":"Mol Ther"},{"key":"1562_CR53","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/mt.2009.286","volume":"18","author":"EA Markakis","year":"2010","unstructured":"Markakis EA, Vives KP, Bober J, Leichtle S, Leranth C, Beecham J, Elsworth JD, Roth RH, Samulski RJ, Redmond DE Jr (2010) Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Mol Ther 18:588\u2013593","journal-title":"Mol Ther"},{"key":"1562_CR54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.mt.6300049","volume":"15","author":"D Sondhi","year":"2007","unstructured":"Sondhi D, Hackett NR, Peterson DA, Stratton J, Baad M, Travis KM, Wilson JM, Crystal RG (2007) Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther 15:481\u2013491","journal-title":"Mol Ther"},{"key":"1562_CR55","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ymthe.2005.11.015","volume":"13","author":"CN Cearley","year":"2006","unstructured":"Cearley CN, Wolfe JH (2006) Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 13:528\u2013537","journal-title":"Mol Ther"},{"key":"1562_CR56","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/gt.2014.103","volume":"22","author":"R Thwaite","year":"2015","unstructured":"Thwaite R, Pages G, Chillon M, Bosch A (2015) AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy. Gene Ther 22:196\u2013201","journal-title":"Gene Ther"},{"key":"1562_CR57","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/gt.2014.47","volume":"21","author":"Q Liu","year":"2014","unstructured":"Liu Q, Huang W, Zhang H, Wang Y, Zhao J, Song A, Xie H, Zhao C, Gao D, Wang Y (2014) Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Ther 21:732\u2013738","journal-title":"Gene Ther"},{"key":"1562_CR58","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27:59\u201365","journal-title":"Nat Biotechnol"},{"key":"1562_CR59","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","volume":"17","author":"S Duque","year":"2009","unstructured":"Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, Fyfe J, Moullier P, Colle MA, Barkats M (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17:1187\u20131196","journal-title":"Mol Ther"},{"key":"1562_CR60","first-page":"42","volume":"8","author":"DJ Schuster","year":"2014","unstructured":"Schuster DJ, Dykstra JA, Riedl MS, Kitto KF, Belur LR, McIvor RS, Elde RP, Fairbanks CA, Vulchanova L (2014) Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat 8:42","journal-title":"Front Neuroanat"},{"key":"1562_CR61","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","volume":"19","author":"SJ Gray","year":"2011","unstructured":"Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ (2011) Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19:1058\u20131069","journal-title":"Mol Ther"},{"key":"1562_CR62","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/hum.2015.170","volume":"27","author":"LK Winner","year":"2016","unstructured":"Winner LK, Beard H, Hassiotis S, Lau AA, Luck AJ, Hopwood JJ, Hemsley KM (2016) A pre-clinical study evaluating AAVrh10-based gene therapy for Sanfilippo syndrome. Hum Gene Ther 27:363\u2013375","journal-title":"Hum Gene Ther"},{"key":"1562_CR63","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","volume":"25","author":"M Tardieu","year":"2014","unstructured":"Tardieu M, Zerah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C, Vincent F, Hocquemiller M, Broissand C, Furlan V et al (2014) Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial. Hum Gene Ther 25:506\u2013516","journal-title":"Hum Gene Ther"},{"key":"1562_CR64","doi-asserted-by":"crossref","first-page":"10229","DOI":"10.1523\/JNEUROSCI.3558-04.2004","volume":"24","author":"A Cressant","year":"2004","unstructured":"Cressant A, Desmaris N, Verot L, Brejot T, Froissart R, Vanier MT, Maire I, Heard JM (2004) Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J Neurosci 24:10229\u201310239","journal-title":"J Neurosci"},{"key":"1562_CR65","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2010.265","volume":"19","author":"NM Ellinwood","year":"2011","unstructured":"Ellinwood NM, Ausseil J, Desmaris N, Bigou S, Liu S, Jens JK, Snella EM, Mohammed EE, Thomson CB, Raoul S et al (2011) Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 19:251\u2013259","journal-title":"Mol Ther"},{"key":"1562_CR66","unstructured":"Unknown (2016) Intra-cerebral gene therapy for Sanfilippo type B syndrome."},{"key":"1562_CR67","unstructured":"Unknown (2015) Positive Topline Results Announced from Phase I\/II Trial in Sanfilippo B Syndrome Patients Using uniQure\u2019s Novel AAV5-Based Gene Therapy, Globe Newswire, Amsterdam, the Netherlands"},{"key":"1562_CR68","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1038\/mt.2014.135","volume":"22","author":"C Hinderer","year":"2014","unstructured":"Hinderer C, Bell P, Gurda BL, Wang Q, Louboutin JP, Zhu Y, Bagel J, O'Donnell P, Sikora T, Ruane T et al (2014) Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. Mol Ther 22:2018\u20132027","journal-title":"Mol Ther"},{"key":"1562_CR69","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ymgme.2014.12.027","volume":"114","author":"P Bell","year":"2015","unstructured":"Bell P, Gurda B, Zhu Y, Sikora T, Ruane T, O'Donnell P, Haskins ME, Wilson JM (2015) Evaluating the impact of systemic AAV9.cIDUA administration on brain pathology in MPS I dogs. Mol Genet Metab 114:S25","journal-title":"Mol Genet Metab"},{"key":"1562_CR70","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/mt.2015.99","volume":"23","author":"C Hinderer","year":"2015","unstructured":"Hinderer C, Bell P, Louboutin JP, Zhu Y, Yu H, Lin G, Choa R, Gurda BL, Bagel J, O'Donnell P et al (2015) Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates. Mol Ther 23:1298\u20131307","journal-title":"Mol Ther"},{"key":"1562_CR71","unstructured":"Unknown (2015) ReGenXBio licenses key technologies from University of Pennsylvania and University of Minnesota for the development of treatments for MPS I and MPS II, REGENXBIO, Washington, DC"},{"key":"1562_CR72","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86696","volume":"1","author":"S Motas","year":"2016","unstructured":"Motas S, Haurigot V, Garcia M, Marco S, Ribera A, Roca C, Sanchez X, Sanchez V, Molas M, Bertolin J et al (2016) CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome). JCI Insight 1:e86696","journal-title":"JCI Insight"},{"key":"1562_CR73","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.ymgme.2015.12.261","volume":"117","author":"H Fu","year":"2016","unstructured":"Fu H, Zaraspe K, Meadows A, Camboni M, McCarty DM (2016) Functional benefits of systemic rAAV9-hids gene delivery in MPS II mouse model. Mol Genet Metab 117:S47","journal-title":"Mol Genet Metab"},{"key":"1562_CR74","unstructured":"Unknown (2016) Esteve and UAB expand their research to two new gene therapies for Sanfilippo B syndrome and Hunter syndrome, PRNewswire, Barcelona."},{"key":"1562_CR75","unstructured":"Unknown (2016) FDA grants rare pediatric disease designation to REGENXBIO\u2019s RGX-121 gene therapy for the treatment of mucopolysaccharidosis type II (MPS II), Globe Newswire, Rockville, MD."},{"key":"1562_CR76","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.ymgme.2013.12.173","volume":"111","author":"DM McCarty","year":"2014","unstructured":"McCarty DM, Zaraspea K, Murreya D, Warea T, Fu H (2014) Functional correction and reversal of MPS IIIA in a mouse model by an intravenous hSGSH gene delivery using a self-complementary AAV9 vector. Mol Genet Metab 111:S75","journal-title":"Mol Genet Metab"},{"key":"1562_CR77","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/hum.2012.029","volume":"23","author":"A Ruzo","year":"2012","unstructured":"Ruzo A, Marco S, Garcia M, Villacampa P, Ribera A, Ayuso E, Maggioni L, Mingozzi F, Haurigot V, Bosch F (2012) Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum Gene Ther 23:1237\u20131246","journal-title":"Hum Gene Ther"},{"key":"1562_CR78","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1172\/JCI66778","volume":"123","author":"V Haurigot","year":"2013","unstructured":"Haurigot V, Marco S, Ribera A, Garcia M, Ruzo A, Villacampa P, Ayuso E, Anor S, Andaluz A, Pineda M et al (2013) Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest 123:3254\u20133271","journal-title":"J Clin Invest"},{"key":"1562_CR79","unstructured":"Unknown (2016) Abeona therapeutics announces FDA allowance of investigational new drug (IND) for systemic AAV phase 1\/2 clinical study with ABO-102 gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA), Marketwired, New York, NY and Cleveland, OH"},{"key":"1562_CR80","unstructured":"Unknown (2016) Abeona therapeutics announces initial European regulatory approvals for phase 1\/2 gene therapy clinical studies for patients with Sanfilippo syndromes type A (MPS IIIA) and type B (MPS IIIB), Marketwired New York, NY and Cleveland, OH"},{"key":"1562_CR81","unstructured":"Unknown (2017) Abeona therapeutics announces top-line data for ABO-102 phase 1\/2 MPS IIIA gene therapy trial at ASGCT, Globe Newswire, New York, NY\u00a0and Cleveland, OH"},{"key":"1562_CR82","unstructured":"Unknown (2017) Abeona therapeutics provides update from ABO-102 phase 1\/2 MPS IIIA clinical trial at the 13th Annual WORLDSymposium\u2122 2017, Globe Newswire New York, NY\u00a0and Cleveland, OH"},{"key":"1562_CR83","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","volume":"19","author":"H Fu","year":"2011","unstructured":"Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM (2011) Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 19:1025\u20131033","journal-title":"Mol Ther"},{"key":"1562_CR84","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/humc.2015.132","volume":"26","author":"AS Meadows","year":"2015","unstructured":"Meadows AS, Duncan FJ, Camboni M, Waligura K, Montgomery CL, Zaraspe K, Naughton BJ, Bremer WG, Shilling C, Walker C et al (2015) A GLP-compliant toxicology and biodistribution study: systemic delivery of a rAAV9 vector for the treatment of mucopolysaccharidosis IIIB. Hum Gene Ther Clin Dev 26:228\u2013242","journal-title":"Hum Gene Ther Clin Dev"},{"key":"1562_CR85","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/humc.2013.208","volume":"25","author":"DA Murrey","year":"2014","unstructured":"Murrey DA, Naughton BJ, Duncan FJ, Meadows AS, Ware TA, Campbell KJ, Bremer WG, Walker CM, Goodchild L, Bolon B et al (2014) Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. Hum Gene Ther Clin Dev 25:72\u201384","journal-title":"Hum Gene Ther Clin Dev"},{"key":"1562_CR86","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/hmg\/ddu727","volume":"24","author":"A Ribera","year":"2015","unstructured":"Ribera A, Haurigot V, Garcia M, Marco S, Motas S, Villacampa P, Maggioni L, Leon X, Molas M, Sanchez V et al (2015) Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy. Hum Mol Genet 24:2078\u20132095","journal-title":"Hum Mol Genet"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-017-1562-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-017-1562-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-017-1562-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T03:47:08Z","timestamp":1659152828000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-017-1562-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,29]]},"references-count":86,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["1562"],"URL":"https:\/\/doi.org\/10.1007\/s00109-017-1562-0","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,29]]}}}